Growth Metrics

Vertex Pharmaceuticals (VRTX) EBT Margin (2009 - 2026)

Vertex Pharmaceuticals' quarterly EBT Margin came in at 41.95% in Q1 2026, up 1558.0% year-on-year from 2.53% in Q1 2025, and up 0.53% quarter-over-quarter from 41.72% in Q4 2025.

Vertex Pharmaceuticals has reported EBT Margin for 18 years, with the latest figure at 41.95% in Q1 2026.

  • For the quarter ending Q1 2026, EBT Margin rose 1558.0% year-over-year to 41.95%; the trailing twelve-month figure through Mar 2026 stood at 42.28% (up 4498.0% YoY), and the FY2025 full-year result was 38.69%, up 3643.0% from the prior year.
  • EBT Margin for Q1 2026 stood at 41.95%, up from 41.72% in the prior quarter.
  • The five-year high for EBT Margin was 50.4% in Q3 2022, with the low at 128.18% in Q2 2024.
  • Average EBT Margin over 5 years is 33.21%, with a median of 44.16% recorded in 2024.
  • Year-over-year, EBT Margin plunged 17477 bps in 2024 and jumped 17146 bps in 2025.
  • Tracing VRTX's EBT Margin over 5 years: stood at 46.76% in 2022, then declined by 3 bps to 45.58% in 2023, then fell by 14 bps to 39.03% in 2024, then increased by 7 bps to 41.72% in 2025, then climbed by 1 bps to 41.95% in 2026.
  • The last three EBT Margin figures came in at 41.95% (Q1 2026), 41.72% (Q4 2025), and 42.22% (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBT Margin (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -6.40%
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 41.95%
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 23.05%
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 18.99%
10 Revolution Medicines 32.39 Bn 32.39 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 41.95%
Dec 31, 2025 41.72%
Sep 30, 2025 42.22%
Jun 30, 2025 43.28%
Mar 31, 2025 26.37%
Dec 31, 2024 39.03%
Sep 30, 2024 44.16%
Jun 30, 2024 -128.18%
Mar 31, 2024 47.54%
Dec 31, 2023 45.58%
Sep 30, 2023 47.48%
Jun 30, 2023 46.59%
Mar 31, 2023 37.54%
Dec 31, 2022 46.76%
Sep 30, 2022 50.40%
Jun 30, 2022 46.64%
Mar 31, 2022 45.52%
Dec 31, 2021 42.02%
Sep 30, 2021 54.57%
Jun 30, 2021 -2.46%
Mar 31, 2021 47.61%
Dec 31, 2020 54.59%
Sep 30, 2020 48.49%
Jun 30, 2020 54.10%
Mar 31, 2020 43.40%
Dec 31, 2019 434.50%
Sep 30, 2019 7.44%
Jun 30, 2019 34.75%
Mar 31, 2019 37.30%
Dec 31, 2018 3.73%
Sep 30, 2018 17.40%
Jun 30, 2018 28.80%
Mar 31, 2018 33.50%
Dec 31, 2017 17.26%
Sep 30, 2017 -72.15%
Jun 30, 2017 6.53%
Mar 31, 2017 35.47%
Dec 31, 2016 4.43%
Sep 30, 2016 -9.53%
Jun 30, 2016 -4.23%
Mar 31, 2016 -7.69%
Dec 31, 2015 -18.71%
Sep 30, 2015 -30.57%
Jun 30, 2015 -114.92%
Mar 31, 2015 -151.60%
Dec 31, 2014 -123.55%
Sep 30, 2014 -121.50%
Jun 30, 2014 -129.49%
Mar 31, 2014 -195.28%
Dec 31, 2013 -15.19%
Sep 30, 2013 -53.63%
Jun 30, 2013 -21.11%
Mar 31, 2013 -132.10%
Dec 31, 2012 -24.18%
Sep 30, 2012 -1.52%
Jun 30, 2012 -3.44%
Mar 31, 2012 23.42%
Dec 31, 2011 37.42%
Sep 30, 2011 47.81%
Mar 31, 2011 -239.06%
Dec 31, 2010 -275.31%
Sep 30, 2010 -878.16%
Jun 30, 2010 -632.49%
Mar 31, 2010 -730.22%
Dec 31, 2009 -445.44%
Sep 30, 2009 -599.29%
Jun 30, 2009 -834.05%
Mar 31, 2009 -678.39%